RemeGen Co (RemeGen Co) Selling and Marketing Expense : $52.02 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. RemeGen Co's Selling and Marketing Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $52.02 Mil.

RemeGen Co Selling and Marketing Expense Historical Data

The historical data trend for RemeGen Co's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Selling and Marketing Expense Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Selling and Marketing Expense

Get a 7-Day Free Trial

0.09

3.70

41.29

63.21

108.57

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Selling and Marketing Expense	Get a 7-Day Free Trial									23.39	-	25.98	-	26.04

RemeGen Co Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.02 Mil.

RemeGen Co Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (RemeGen Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Selling and Marketing Expense

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).